Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crestor Label Lends Validity To Controversial C-Reactive Protein Test

Executive Summary

FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say
Advertisement

Related Content

Esperion's Oral Bempedoic Acid Passes First Phase III Cholesterol Test
Where Cholesterol Surrogates Stand After ACC '16
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
Bad News/Good News For Cholesterol: Another Strike Against HDL, But Support For Stricter LDL Targets
Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs
Lipitor Study Creates More Doubts On CRP Study Used To Expand Crestor Label
As Crestor Patent Trial Nears, Generic Firms Seek To Block AstraZeneca Subsidiary From Suit
Crestor Advisory Meeting Weighs Value Of C-Reactive Protein Risk Marker
Crestor Advisory Meeting Weighs Value Of C-Reactive Protein Risk Marker
Will JUPITER Change Statin Use?

Topics

Advertisement
UsernamePublicRestriction

Register

PS051928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel